KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Equity Average (2016 - 2025)

Historic Equity Average for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $559.4 million.

  • Emergent BioSolutions' Equity Average rose 2503.63% to $559.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $559.4 million, marking a year-over-year increase of 2503.63%. This contributed to the annual value of $566.0 million for FY2024, which is 4442.32% down from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Equity Average is $559.4 million, which was up 2503.63% from $544.4 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Equity Average registered a high of $1.6 billion during Q1 2022, and its lowest value of $447.4 million during Q3 2024.
  • Its 5-year average for Equity Average is $1.0 billion, with a median of $1.1 billion in 2023.
  • As far as peak fluctuations go, Emergent BioSolutions' Equity Average surged by 3746.13% in 2021, and later tumbled by 5226.36% in 2023.
  • Emergent BioSolutions' Equity Average (Quarter) stood at $1.6 billion in 2021, then decreased by 10.0% to $1.4 billion in 2022, then crashed by 52.26% to $673.2 million in 2023, then dropped by 26.39% to $495.6 million in 2024, then grew by 12.86% to $559.4 million in 2025.
  • Its Equity Average was $559.4 million in Q3 2025, compared to $544.4 million in Q2 2025 and $517.8 million in Q1 2025.